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Abstract
The proteasome inhibitor Velcade (bortezomib/PS-341)
has been shown to block the targeted proteolytic deg-
radation of short-lived proteins that are involved in cell
maintenance, growth, division, and death, advocating
the use of proteasomal inhibitors as therapeutic agents.
Although many studies focused on the use of one pro-
teasomal inhibitor for therapy, we hypothesized that
the combination of proteasome inhibitors Lactacystin
(AG Scientific, Inc., San Diego, CA) and MG132 (Biomol
International, Plymouth Meeting, PA) may be more ef-
fective in inducing apoptosis. Additionally, this regimen
would enable the use of sublethal doses of individual
drugs, thus reducing adverse effects. Results indicate
a significant increase in apoptosis when LNCaP pros-
tate cancer cells were treated with increasing levels
of Lactacystin, MG132, or a combination of sublethal
doses of these two inhibitors. Furthermore, induction
in apoptosis coincided with a significant loss of IKKa,
IKKb, and IKKg proteins and NFnB activity. In addition to
describing effective therapeutic agents, we provide a
model system to facilitate the investigationof themecha-
nism of action of these drugs and their effects on the
IKK–NFnB axis.
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Introduction
Removal of androgens induces apoptosis and drives
androgen-sensitive prostate cancer into remission. Despite
androgen depletion therapy and remission, prostate cancer
survivors may develop a subclass of androgen-refractory
cancer that is oftenmore aggressive than the primary cancer
[1]. This and other transformations have been associated
with an increase in the prosurvival and proliferative activities
of NFnB [2,3]. As a result, the regulation, processing, and
disruption of NFnB are being explored as chemotherapeu-
tic targets in cancer [4,5]. Of the members of the NFnB
family, p65 is one of the most studied transcription factors,
as it is involved in short-term and long-term cell survival and
is active at both the nuclear and mitochondrial levels [4–8].
The transcriptional activity of p65 is regulated by inhibitor
of nB (InB) proteins that bind to the Rel Homology Domain
of NFnB and prevent the translocation and transcriptional
activity of NFnB [9]. To disrupt the binding of InB to NFnB and
to increase NFnB activity, InB kinase proteins IKKa, IKKb, and
IKKg are required. These proteins are located throughout the
cytosol as either trimers of a, b, and g subunits; dimers of b and
g; or monomers of IKKa [10,11]. Once phosphorylated, IKK pro-
teins increase the transcriptional activity of NFnB directly and/
or indirectly. For instance, phosphorylation of InBa by IKKb re-
sults in the immediate ubiquitination and degradation of InBa by
the 26S proteasome, thereby unmasking the nuclear localization
signal of NFnB [4,12,13]. IKKa is a multifunctional protein re-
sponsible for the phosphorylation of IKKb, phosphorylation of
InBa, direct phosphorylation of NFnB, and finally, phosphoryla-
tion of the nuclear histone H3 through CBP/p300 [14,15]; these
cumulative effects facilitate the transcriptional activity of NFnB
[7,16,17]. Theactivation of IKKproteins is necessary for the trans-
location of p65 into the nucleus [8] and the transcriptional acti-
vation of p65 in the nucleus. The process of NFnB activation and
subsequent repression of apoptotic proteinsmay be deregulated
when IKK proteins themselves or regulatory proteins upstream
of IKK activation are blocked, missing, or mutated [3,18–21].
Of the drugs used for cancer therapy, proteasome inhibitors
have shown promise in disrupting regulatory proteins, thereby
reducing and/or eliminating various neoplastic cancers. The
theory behind the use of proteasomal inhibitors is that, of all the
cellular proteins involved in maintenance, differentiation, im-
munity, growth, division, and death, approximately 70% to 90%
is eventually degraded by multicatalytic proteasomes [22–26].
By interfering with the normal function of proteasomes, cellular
stress is induced, leading to cell cycle arrest and/or cell death
[27–29]. Many compounds that either interfere or block protea-
somal function have been identified. These include b-lactones
such as clasto-Lactacystin, peptidyl aldehydes such as MG132
(carbobenzoxy-L-Leu–L-Leu–L-Leu), and peptidyl boronates
such as Velcade (bortezomib/PS-341). Lactacystin (AG Scien-
tific, Inc., San Diego, CA) binds covalently, whereas MG132
(Biomol International, Plymouth Meeting, PA) and Velcade
Address all correspondence to: M. Vijay Kumar, BA 8415, Section of Urology, Medical College
of Georgia, Augusta, GA 30912. E-mail: vkumar@mail.mcg.edu
Received 5 August 2005; Revised 30 September 2005; Accepted 3 October 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05520
Neoplasia . Vol. 7, No. 12, December 2005, pp. 1104 – 1111 1104
www.neoplasia.com
RESEARCH ARTICLE
bind reversibly to the N-terminal Thr residue of the b1 sub-
unit within the 26S proteasome [30,31]. Aside from the anti-
proteasomal activity of Lactacystin and MG132, these
compounds are known inhibitors of other proteases such as
cathepsin A, cathepsin B, and calpain 1 [32,33], respectively.
Regardless of the latter’s protease activity, the primary effect
of the inhibitors is directed on the proteasome. Proteasomal
inhibitors increase the lifespan of short-lived proteins and
block the modification of proteins involved in signaling path-
ways, resulting in changes that inhibit cell survival and pro-
liferation. In early studies, Velcade was reported to induce
DNA damage, arrest cellular cycling at the G1/S or G2/M
phase, and reduceNFnBactivity [34–37].When used to treat
cancer cells, Velcade induced a dose-dependent cleavage of
polyadenosine-5V-diphosphate-ribose polymerase (PARP),
significant apoptosis, expression of p21WAF1, and G2/M cell
cycle arrest [38]. Based on these beneficial effects, Velcade
is being tested in phase I to phase III clinical trials for a variety
of solid tumors. Unfortunately, several side effects, including
incomplete tumor regression, have been noted at the doses
required for the induction of apoptosis [33,39–42], thus
necessitating the identification of other drugs that are effec-
tive at lower doses.
Although proteasomal inhibitors are being tested in cancer
therapy, available data on prostate cancer are sparse. There-
fore, our goal was to examine the effect of proteasomal
inhibitors on prostate cancer. We hypothesized that a com-
bination of proteasome inhibitors (e.g., MG132 and Lacta-
cystin) would induce more apoptosis at lower doses of the
drugs compared to the use of either inhibitor alone. The
following results highlight the advantages of using com-
bination therapy, as the inhibitors synergistically induce apop-
tosis. We also demonstrate that the increase in apoptosis is
associated with a decrease in proteins associated with the
IKK–NFnB axis.
Materials and Methods
Cell Culture and Experimental Design
LNCaP and PC3 cells (American Type Culture Collection,
Rockville, MD) were maintained in RPMI 1640 (Hyclone, Lo-
gan, UT) containing 10% FBS, 0.5% penicillin–streptomycin
(0.05 U/ml) (InVitrogen Corporation, Carlsbad, CA), and 0.1%
Fungizone (0.25 mg/ml) (InVitrogen Corporation). All experi-
ments were conducted with the same stockmedia for 24 hours,
but with an FBS concentration of 7.5%. Cells were treated with
increasing concentrations of Lactacystin in Experiment 1 and
with increasing concentrations of MG132 in Experiment 2.
In Experiment 3, cells were treated with 5.0 mM Lactacystin,
250 mMMG132, or their combination. The activity of NFnB and
p53 was determined in Experiments 4 and 5, respectively. After
LNCaP cells were transfected with a plasmid-based NFjB-
Luciferase or p53-Luciferase reporter construct, they were
treated as in Experiment 3.
Induction of apoptosis wasmeasured using anM30 Apop-
tosense kit (Peviva AB, Bromma, Sweden), which measured
a neoepitope of cytokeratin 18 generated during apoptosis.
Cell extracts were separated on Tris–glycine gels (10–15%)
and were probed for IKKa, IKKb, IKKg, InBa, InBa(S32/36),
phospho-p53(S15), p21
WAF1, caspase-3, XIAP, NFnB1 (p50),
and b-actin. Positive signals were developed using ECL-
Plus (Amersham Biosciences Corp., Pittsburg, PA) and cap-
tured on a digital imager (Alpha Innotech, San Leandro, CA).
Digitized signals were normalized against b-actin to control
for differences in protein loading.
p53 and NFnB Activity Assays
Luciferase reporter activity was measured using a Lu-
ciferase reporter assay (Promega, Madison, WI). In each
experiment, 3.5  106 cells were suspended in an electro-
poration buffer (120mMKCl, 0.15mMCaCl2, 10mMK2HPO4/
KH2PO4, 25 mM HEPES, 2 mM EGTA, 5 mM MgCl2, 50 mM
glutathione, and 2 mM ATP, pH 7.6), transferred to a 4-mm
electroporation cuvette, and mixed with 20 mg of a NFjB-
Luciferase firefly luciferase reporter construct (BD Biosci-
ences Clontech, Palo Alto, CA) or 20 mg of a p53-Luciferase
firefly luciferase reporter construct (Panomics, Inc., Redwood,
CA) . The cells were electroporated using a BTX-830 elec-
troporator (Gentronics, San Diego, CA) with 200-mV voltage,
10-millisecond pulse length, and two pulses at 500-millisecond
intervals. After the cells had rested in the cuvette for 10 min-
utes, they were dispersed in RPMI media. The cells were
seeded at 2.5  105 cells/well of a 12-well culture plate and
allowed to adhere for 24 hours before treatment with the
proteasome inhibitors.
Statistical Analysis
Apoptosense and actin-corrected densitometries of West-
ern blot analysis data were analyzed by the GLM procedure
of SAS (SAS Institute, Inc., Cary, NC) [43], and means were
compared for NFnB and p53 activity data by Duncan’s mul-
tiple range test (P < .01) only when a significant probability
value of .05 was detected in the analysis of variance.
Results
Proteasomal Inhibitors MG132 and Lactacystin
Induce Apoptosis
Treatment of LNCaP cells with Lactacystin induced apop-
tosis (greater than five-fold) at the lowest dose (5 mM) tested
(Figure 1A). The apoptotic response continued linearly up to
12.5 mM Lactacystin (P < .0001; R 2 = 0.956), indicating that
Lactacystin is an effective apoptotic agent in LNCaP prostate
cancer cells. No appreciable cell death was observed with
lower doses of MG132, whereas 0.5 mM induced an approx-
imately two-fold apoptosis (Figure 1B). Further increases in
MG132 resulted in a curvilinear response (P < .0001; R 2 =
0.985), leading to a 13-fold increase in apoptosis at the
3.00-mM dose. To test the hypothesis that the combination
of the two proteasomal inhibitors would provide apoptotic
advantage, LNCaP cells were treated with suboptimal doses
of Lactacystin (5 mM) and MG132 (250 nM). Treatment
with Lactacystin or MG132 alone confirmed the above re-
sults, whereas the combination yielded a highly significant
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increase in apoptosis (7.7-fold), indicating that this regimen
may have therapeutic advantage (Figure 1C).
The above results demonstrated that the proteaso-
mal inhibitors Lactacystin and MG132 induced apoptosis in
androgen-responsive LNCaP cells. As androgen-independent
prostate cancer is a major concern in patients and is more
difficult to treat, it is of interest to determine whether these
proteasomal inhibitors are capable of inducing apoptosis in
androgen-independent prostate cancer cells. Treatment of
PC3 cells with the same suboptimal dose of Lactacystin in-
duced apoptosis (Figure 1D). Furthermore, similar to LNCaP,
treatment of PC3 with 250 nM MG132 induced very little or no
apoptosis, whereas combination of Lactacystin and MG132
resulted in synergistic induction of apoptosis (10-fold increase
compared to cells treated with Lactacystin alone). These
results indicate that the proteasomal inhibitors Lactacystin
and MG132 induced apoptosis in both androgen-responsive
andandrogen-independent prostate cancer cells, an important
therapeutic advantage of these drugs.
To confirm the results of apoptosis, the expression of
p21WAF1 and caspase-3 was determined because an increase
in active caspase-3 was associated with an increase in DNA
cleavage and the expression of p21WAF1 in a p53-dependent
manner. This not only facilitated apoptosis, but also induced
cell cycle arrest. Expression of p21WAF1 increased with each
dose of Lactacystin or MG132 (Figure 2, A and B). The lowest
dose of Lactacystin tested was enough to significantly in-
crease p21WAF1, whereas 500 nM MG132 was required to
elicit a similar response. Combined treatment significantly
increased the levels of p21WAF1 beyond that of either protea-
some inhibitor alone (Figure 2C). A similar analysis showed
that Lactacystin activated caspase-3, as noted by the pres-
ence of proteolytic fragments (Figure 3), whereas activation
was not significant with MG132 alone. Combined treatment
synergistically increased the processing of the 35-kDa pro-
caspase to the 17- and 12-kDa active fragments.
Figure 1. LNCaP cells were treated with 5.0 to 12.5 M Lactacystin (panel A;
Experiment 1), 0.06 to 3.0 M MG132 (panel B; Experiment 2), or their com-
bination (panel C; Experiment 3). PC3 cells were treated as in Experiment 3,
and apoptosis was measured (panel D). Results are fold inductions of M30
activity. Values represent observations from two experiments with three to four
replicates each.
Figure 2. LNCaP cells were treated with increasing concentrations of Lac-
tacystin (panel A; Experiment 1), MG132 (panel B; Experiment 2), or their com-
bination (panel C; Experiment 3) for 24 hours. Expressions of p21 and -actin
were evaluated using Western blot analysis.
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Proteasomal Inhibitors Decrease the Level of IKK Proteins
To further investigate the mechanism of action of these
drugs, the IKK–NFnB axis was investigated starting with the
expression of IKKa, IKKb, and IKKg. A dose-dependent de-
crease in the levels of each of the IKK proteins was observed
with increasing concentrations of Lactacystin (Figure 4A);
however, marginal reduction was observed for IKKa at
the lower levels of Lactacystin. Where the addition of 5 mM
Lactacystin reduced IKKa by 30%, the addition of 8.75 and
12.5 mM Lactacystin reduced IKKa by 50% and 56%, re-
spectively. Although not to the same magnitude, this trend
was similar for IKKb and IKKg. Results obtained with MG132
were similar to those of Lactacystin, except that IKK proteins
decreased significantly only when treated with 0.25 to 3.0 mM
MG132 (Figure 4B). In combination experiments, IKK pro-
teins responded to the individual drugs as in the previous
groups. However, the level of IKKg was significantly reduced
when compared to that of either proteasome inhibitor alone
(Figure 4C). Together, these experiments demonstrated a
significant decrease in all three IKK family members, which
coincided with significant apoptosis with increasing concen-
trations or with a combination of Lactacystin and MG132.
Lactacystin and MG132 Affect InBa and NFnB Proteins
As changes in the function of IKK may affect the activity
of NFnB through their effects on InBa and the proteolytic
modifications of p105 to p50, the levels of total and phos-
phorylated InBa and NFnB1 (p50) were determined. Increas-
ing concentrations of Lactacystin significantly increased the
phosphorylation of InBa, although it had no effect on the
levels of total InBa (Figure 5A). At first glance, these results
seemed contradictive to this established molecular pathway,
as the decrease in IKK should have resulted in a reduction
in the phosphorylated form of InBa. Under control conditions,
phosphorylation of InBa led to ubiquitination and degradation
of InBa by the 26S proteasome. However, inhibition of pro-
teasomal activity by Lactacystin resulted in an increase in
phosphorylated InBa. Similarly, treatment with higher doses
of MG132 increased InBa phosphorylation (Figure 5B). Un-
like Lactacystin, however, treatment with higher doses of
Figure 3. LNCaP cells were treated with Lactacystin (Lact), MG132, or their
combination for 24 hours. Expression levels of caspase-3, cleaved products of
caspase-3, and -actin were evaluated usingWestern blot analysis. Procaspase
signals were obtained after 15 seconds of exposure, and signals from the
cleaved caspase-3 fragments were obtained after a 3-minute exposure to a
radiological film.
Figure 4. LNCaP cells were treated with increasing concentrations of Lac-
tacystin (panel A; Experiment 1), MG132 (panel B; Experiment 2), or their com-
bination (panel C; Experiment 3) for 24 hours. Immunoblots were analyzed for
the expression of IKKa, IKK, IKKc, and -actin. The signal was captured in
digital image analysis units, and arbitrary density units are expressed per actin
value. Values are averages of three replicates from two experiments.
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MG132 resulted in an unexplainable decrease in total levels
of InBa (Figure 5B). Finally, combined treatment with Lacta-
cystin and MG132 resulted in a significant reduction in total
InBa when compared to either individual treatment (Figure 5C);
phosphorylation of InBa increased significantly in cells treated
with both inhibitors. These results indicate that treatment with
proteasomal inhibitors Lactacystin andMG132not only reduced
the levels of IKK, but prolonged the half-life and levels of phos-
phorylated InBa.
A similar analysis ofNFnB1 (p50) demonstrateda steadyde-
crease in its levelswith increasing concentrations of Lactacystin
and/or MG132 (Figure 5), possibly attributed to the decrease in
InBa observed above. It is known that NFnB1 (p105) is pro-
cessed to p50 by the proteasome in response to phosphoryla-
tion by IKKa. Thus, it is likely that the decrease in NFnB1 (p50)
was due to proteasomal inhibition. Given the reduction in both
IKK proteins and p50, it was of interest to determine whether
these drugs affected the activity of NFnB.
Proteasomal Inhibitors Increase NFnB and p53 Activity
AsNFnB is a key target of IKK proteins, the effects of Lacta-
cystin and MG132 on the transcriptional activity of NFnB and
p53 were determined. LNCaP cells were transfected with
NFjB-Luciferase or p53-Luciferase constructs and treated
with Lactacystin and MG132, individually or together. Treat-
ment with Lactacystin induced significant NFnB-Luciferase
activity (P < .0201; R 2 = 0.78), whereas MG132 increased
NFnB-Luciferase activity to a lesser extent (Figure 6A). These
results were contrary to expectations, as IKK levels were
Figure 5. LNCaP cells were treated with increasing concentrations of Lac-
tacystin (panel A; Experiment 1), MG132 (panel B; Experiment 2), or their com-
bination (panel C; Experiment 3) for 24 hours. The effect of treatment on total
IjBa (IjBa), phosphorylated IjBaS32/36 (P-IjBa), and NFjB1 (p50) was ana-
lyzed by Western blot analysis. Values are averages of at least three replicates
from two experiments.
Figure 6. LNCaP cells were treated with a combination of Lactacystin and
MG132 for 24 hours. NFjB (panel A; Experiment 4) and p53 (panel B;
Experiment 5). Luciferase activity was expressed as relative light units (RLU)
per microgram of cellular protein. Values are averages of two experiments
with three replicates per treatment.
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reduced in these cells (Figure 4C). The significance of these
results is discussed below.
p53-Luciferase activity in Lactacystin- and MG132-
treated cells (Figure 6B) agrees with p21WAF1 expression data
(Figure 2C). Although the combination of Lactacystin and
MG132 increased p53 activity (P < .0001; R 2 = 0.96), it was
lower than that of Lactacystin alone. This was at variance with
the expression of p21WAF1 in these cells. This was probably
due to the transcriptional regulation of the p53 construct by
other members of the p53 protein family (such as p73).
Discussion
It is known that the proteasome is responsible for degrading
70% to 90% of all cellular proteins. The proteasome serves as
a regulatory body that modifies proteins to render them
functional (e.g., NFnB: p105 to p50), or that degrades proteins
(e.g., p21WAF1 or active caspase-3) when they are no longer
needed [44–46]. Although the proteasomal inhibitor Velcade
is being tested in clinical trials, to date, there has been no re-
port on the concurrent use of more than one class of pro-
teasome inhibitors in the treatment of cancer. Therefore, the
current study was designed to test the hypothesis that the
combination of small doses of two different proteasome inhib-
itors would significantly induce apoptosis in prostate cancer
when compared to the use of one proteasome inhibitor alone.
Results from a series of experiments in this study indicate
that the combination of Lactacystin and MG132 facilitates a
high degree of cell death by inducing apoptosis, while simul-
taneously decreasing the expression of prosurvival proteins.
Cancer cells express a plethora of prosurvival proteins that
override death-promoting signals in normal cells. Therefore,
the goal of this study is to design therapy geared toward
promoting the survival of death-inducing proteins. This is
achieved by inhibiting the function of proteasomes. Our results
showed a 39% increase in apoptosis when LNCaP cells were
concurrently treated with Lactacystin and MG132. This effect
may be due to changes in both the level and activity of
proapoptotic and antiapoptotic proteins. Inhibitor-induced de-
crease in IKK proteins and processing of p105 to p50may lead
to a decrease in the function of prosurvival proteins, such as
XIAP, BCL2, BCLXL, and MCL-1. Moreover, stabilization and
expression of proapoptotic proteins in treated cells induced
higher apoptosis and overcame the protection of survival pro-
teins. These two scenarios are supported by the present re-
sults. Tang et al. [47] overexpressed caspase-3 inMCF-7 cells
and observed a caspase-3–mediated cleavage of IKKbwhen
MCF-7 and HeLa cells were treated with TNFa. As observed,
increased caspase-3 activity in treated cells may have led
to an enhanced proteolytic cleavage of IKKb. Despite the
reduction in IKK proteins and contrary to expectations, phos-
phorylation of InBa increased in Lactacystin- and MG132-
treated cells due to the inhibition of proteasomal activity. The
increase in Lactacystin-mediated InBa phosphorylation was
likely responsible for the observed increase in NFnB activity.
Surprisingly, increased NFnB activity in Lactacystin-treated
cells coincided with enhanced apoptosis, providing an inter-
esting model that can be used to further explore the mecha-
nisms involved in apoptotic response, including proapoptotic
functions of NFnB.
Many short-lived proteins are known to induce apopto-
sis. Activated caspase-3 induces DNA damage through the
cleavage of PARP and BRCA1, which signals ATM and ATR
to directly phosphorylate p53, thereby increasing the stability
and transcriptional activity of p53 [48,49]. Our results dem-
onstrate increased p53 transcriptional activity in Lactacystin-
treated cells correlating with apoptosis. Although MG132, by
itself, did not increase transcriptional activity, a combination
of Lactacystin and MG132 resulted in lower luciferase ac-
tivity. These results are similar to other observations in which
increased levels of Velcade were used to treat a variety of
cancers. Williams and McConkey [50] reported an increase
in not only the stability of nuclear MDM2-P53, but also in the
ability of the complex to bind a p53 DNA consensus se-
quence. The increase in p53 activity observed in proteaso-
mal inhibitor–treated cells is significant in light of the report
that p53 repressed the expression of IKKa by competitively
sequestering ETS-1 from the IKKa promoter [51]. This may
explain the observed decrease in IKKa and the increase
in p21WAF1, which may be responsible for the decreased
activity of NFnB. The high degree of NFnB activity in pro-
teasome inhibitor–treated LNCaP cells may be due to the
crosstalk between NFnB and p53 [52,53]. Furthermore an
NFnB-binding site has been demonstrated in the p53 gene,
suggesting that an increase in NFnB activity could increase
the level of p53 protein expression [54].
Conclusion
Arresting proteasome function with Velcade has certainly
proven to be beneficial in arresting the progression of tumor-
igenesis. Preclinical and clinical trials demonstrate the need
to improve the efficiency and efficacy of the drug [35,38,55–
58]. The present study suggests that the treatment of pros-
tate cancer with two chemically distinct proteasome inhibitors
may be superior to the use of any one proteasome inhibitor
alone. In this preliminary report, the effectiveness of protea-
somal inhibitors is the sum total of its effects on both the
apoptotic and the antiapoptotic pathways in cancer cells.
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